98%
921
2 minutes
20
Objectives: Oral lichen planus (OLP) is a chronic inflammatory disorder of the oral mucosa, genetic and molecular alterations, including mutations in the p53 tumor suppressor gene, have been implicated in OLP pathogenesis. However, its molecular mechanisms are not clearly understood. This study investigates p53 gene mutations in OLP lesions.
Material And Methods: This study analyzed 43 paraffin-embedded tissue blocks from OLP patients. Diagnosis was confirmed by two pathologists. Genomic DNA was extracted using a commercial kit, with quality and quantity assessed by spectrophotometry and agarose gel electrophoresis. PCR-sequencing was performed on exons 5-8 and part of the adjacent introns of the p53 gene. Statistical analysis was performed using SPSS version 20, with Fisher's exact test and t-test applied to assess relationships between p53 mutations and clinical parameters; significance was set at p < 0.05.
Results: The study included 43 OLP cases (mean age 51.7 ± 13.3 years; 65.1% female). Lesions were most frequently located on the buccal mucosa (65.1%), followed by the tongue (20.9%), gingiva (19.3%), and mandible (4.7%). DNA sequencing identified 13 nucleotide changes in the p53 gene in 9 samples (20.9%), distributed across exons 5-7 and intronic regions at codons 140, 171, 185, 213, and 246, as well as at IVS4: +8(C/G), IVS7: -11(A/C), and IVS4: -18(A/T). Mutations included equal proportions of missense and silent changes, as well as transitions and transversions. Adenine mutations were most common (53.8%), followed by cytosine mutations (30.8%). No statistically significant associations were found between p53 mutations and patient gender, age, or anatomical site of sampling.
Conclusions: The study identified p53 gene mutations in 21% of oral lichen planus (OLP) cases, with no demographic or pathological correlations. While highlighting p53's complex role and potential as a biomarker, limited sample size necessitates larger, multi-center studies to clarify genetic/environmental influences on OLP pathogenesis and mutation predisposition.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12392420 | PMC |
http://dx.doi.org/10.1002/cre2.70206 | DOI Listing |
Phytomedicine
August 2025
Key Laboratory of Emergency and Trauma of Ministry of Education, Engineering Research Center for Hainan Biological Sample Resources of Major Diseases, the Hainan Branch of National Clinical Research Center for Cancer, the First Affiliated Hospital, Hainan Medical University, Haikou 571199, China; Ke
Background: Traditional Chinese medicine (TCM) has shown anti-tumor potential, but its molecular mechanisms remain poorly understood. This integrated bioinformatics, network pharmacology, and experimental study investigated the anti-cancer effects and mechanisms of Dendrobin A, a pharmacologically active bibenzyl compound from Dendrobium nobile, in gastric cancer (GC).
Methods: Differentially expressed genes (DEGs) were identified through analysis of the TCGA-STAD dataset.
Cell Rep
September 2025
Department of Chemical Engineering, MIT, Cambridge, MA 02139, USA. Electronic address:
Cell states evolve through the combined activity of signaling pathways and gene networks. While transcription factors can direct cell fate, these factors rely on a receptive cell state. How signaling levels contribute to the emergence of receptive cell states remains poorly defined.
View Article and Find Full Text PDFMol Med Rep
November 2025
Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
Asprosin is glucogenic adipokine that exerts a wide repertoire of actions, including the regulation of appetite, insulin resistance and cell proliferation. At present, little is known about the actions of asprosin in the human placenta. The present study investigated the effects of asprosin on the transcriptome of the BeWo and JEG‑3 placental cell lines, and assessed the expression of FBN1/Furin and asprosin's candidate receptors in healthy placentas when compared against placentas from pregnancies where the carrier had gestational diabetes mellitus (GDM).
View Article and Find Full Text PDFFront Oncol
August 2025
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia.
mutations drive oncogenesis and therapeutic resistance in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML), impairing p53-regulated functions such as apoptosis, immune surveillance, and genomic stability, leading to immune evasion and metabolic reprogramming. The tumor microenvironment in -mutated MDS and AML fosters leukemic progression through cytokine dysregulation, altered metabolism, and immune suppression. Current therapies, including chemotherapy and hypomethylating agents, offer limited efficacy, resulting in poor overall survival rates for these high-risk patients.
View Article and Find Full Text PDFAcute myeloid leukemia (AML) is a heterogeneous disease characterized by a broad spectrum of molecular alterations that influence clinical outcomes. TP53 mutations define one of the most lethal subtypes of acute myeloid leukemia (AML), driving resistance to nearly all available treatment modalities, including venetoclax plus azacitidine (VenAza). Yet, the molecular basis of this resistance, beyond affecting transactivation of BCL-2 family genes, has remained elusive.
View Article and Find Full Text PDF